Notice of Appeal
Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma after 2 or more systemic treatments (review of TA677) [ID6325]
NICE has received 1 appeal that falls within one or more of the two strictly limited grounds for appeal, against the Final Draft Guidance on the above technology from the following organisation:
- Gilead Sciences Ltd
The appeal panel will convene on Monday 30 March 2026 at 10am via Zoom to hear oral representations from the appellants.
Members of the public, including consultees and commentators for this appraisal, and the press, may request to attend the hearing.
Where possible, requests to attend should be made using the registration link that will be available on our website from Wednesday 4 February 2026. The registration period for this appeal will end at 4:00pm on Monday 23 March 2026.
Further details relating to public attendance at this appeal are available on the same webpage as above.